Navigation Links
Heart Hospital of Austin First in World to Use New Device for Blocked Arteries
Date:1/8/2009

New magnetically-navigated guidewire provides minimally-invasive treatment for Peripheral Artery Disease

AUSTIN, Texas, Jan. 8 /PRNewswire/ -- The Heart Hospital of Austin is the first hospital in the world to use the new Stereotaxis RF PowerAssert(TM) Magnetic Guidewire to successfully treat chronic total occlusions (CTOs), or complete blockages in patients with peripheral artery disease.

Austin Heart interventional cardiologist, Frank Zidar, M.D. used the new device on Wednesday, January 7, 2009, on a patient with severe peripheral artery disease (PAD). The patient had 100% blockage in a main artery in his leg. Without proper treatment, he would continue to experience chronic, severe pain in his leg due to poor circulation, according to a hospital spokesperson.

"Traditional treatment for blocked arteries uses manual guidewires to travel through the artery to the area of blockage in the leg. This can be extremely challenging because these guidewires are very difficult to maneuver. This new magnetic guidewire technology allows for greater control and improved accuracy," explains Dr. Frank Zidar.

"Once the blockage is reached, the tip of the guidewire can burn or ablate a tiny passage through the blockage, allowing us then to use existing techniques to open up the blockage further. This revolutionary technology will likely reduce procedure times and therefore reduce the amount of contrast dye and imaging radiation to the patient," he added.

Peripheral Artery Disease affects eight to twelve million Americans, according to the American Heart Association. If left untreated, patients can experience ulcerations and gangrene that significantly increase their risk of losing a limb or even result in death.

The Stereotaxis RF PowerAssert(TM) Magnetic Guidewire was approved by the FDA in August 2008. It is the only magnetically enabled device capable of intra-lesion steering available for crossing completely blocked arteries.

Heart Hospital of Austin was chosen as one of only two clinical sites in the world to study the efficacy of the new Stereotaxis RF PowerAssert(TM) Magnetic Guidewire.


'/>"/>
SOURCE Heart Hospital of Austin
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Submits IDE Application for a Pivotal Bridge-to-Transplant Study of the Levacor(TM) VAD
2. Mortality rates higher for heart disease patients in poorer B.C. neighborhoods
3. CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial
4. Heart Drug May Be a Cancer Fighter
5. Traditional risk assessment tools do not accurately predict coronary heart disease
6. New SMHEART LINK(TM) Technology Allows iPhones to Double as Fitness Monitors
7. Randy Jackson and the American Heart Association Encourage Philadelphia Residents to Get In The K.N.O.W. About Improving Type 2 Diabetes Management
8. New appropriate use criteria guide treatment of patients with heart blockage
9. Viagra May Shield Heart From Blood Pressure Damage
10. New hope for cancer comes straight from the heart
11. When the Heart Stops Beating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: